Product Description
Mechanisms of Action: MMP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer
Phase 2: Brain Stem Cancer|Glioblastoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
AG-3340-019 | P2 |
Completed |
Glioblastoma|Brain Stem Cancer |
2002-01-01 |
|
AG-3340-017 | P3 |
Completed |
Non-Small-Cell Lung Cancer |
2001-07-01 |